Kardium Announces First Patient Enrollment in the Globe Registry, Expanding Real-World Evidence for the Globe® Pulsed Field System Following Strong Early Commercial Experience

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Kardium Announces First Patient Enrollment in the Globe Registry, Expanding Real-World Evidence for the Globe® Pulsed Field System Following Strong Early Commercial ExperienceAuthor of the article:The Globe mapping and ablation catheter from Kardium. Business WireVANCOUVER, British Columbia — Kardium today announced the first site activation and first patient enrollment in the Globe Registry: Globe® Pulsed Field System Registry for Treating Patients with Symptomatic Atrial Fibrillation.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe registry marks an important milestone in the continued commercial adoption of the Globe System following positive physician experience, strong procedural outcomes, and a growing body of evidence supporting the system’s unique integrated mapping and ablation approach.This advertisement has not loaded yet, but your article continues below.Overlake Medical Center in Bellevue, Washington enrolled the first patient in the registry.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“As one of the first participating centers, we are pleased to contribute to the collection of real-world evidence supporting this technology,” said Maheer Gandhavadi, MD, Medical Director of Electrophysiology at Overlake Medical Center. “Our experience with the Globe System has been extremely encouraging thanks to the high-definition mapping and configurability of the lesions delivered. Patients treated with the device have done tremendously well, with low rates of recurrence and excellent clinical outcomes observed to date. We look forward to continuing to use the Globe System in routine clinical practice.”The Globe System received regulatory approval from Health Canada in July 2026 and the U.S. Food and Drug Administration (FDA) in August 2025.“We are incredibly excited by what we’re seeing with the Globe System in early commercial use,” said Kevin Chaplin, Chief Executive Officer of Kardium. “We’re hearing positive feedback from physicians who have used the device across a broad range of cases. These results reinforce our belief that the Globe System represents a meaningful advancement in AFib treatment. As use of the technology expands, the Globe Registry will provide an important opportunity to capture real-world data that demonstrates the clinical value physicians are already experiencing in practice.”The Globe Registry is a prospective, post-approval, multicenter, single-arm observational registry designed to evaluate the long-term safety and effectiveness of the Globe System for treating patients with atrial fibrillation. The registry is expected to enroll up to 500 patients across multiple sites in the United States and Canada. Patients will be followed for 12 months post-procedure to evaluate treatment effectiveness.About the Globe® Pulsed Field SystemThe Globe System is an integrated cardiac mapping and ablation system designed to advance the treatment of atrial fibrillation (AF), the most common sustained cardiac arrhythmia. It combines high-density mapping and pulsed field ablation in a single catheter, providing physicians with real-time information to guide catheter positioning, assess tissue contact, and deliver targeted treatment.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.